1. At a Glance

Sanofi Consumer Healthcare India Ltd (SCHIL) – the newborn child of Sanofi India’s 2023 demerger – trades at a spicy ₹4,940 with a market cap of ₹11,378 Cr. The company is basically your neighbourhood chemist’s favourite shelf: Combiflam (pain), Allegra & Avil (allergy), and DePURA (Vitamin D). Sales TTM stand at ₹724 Cr, PAT at ₹198 Cr, with operating margins flexing at 35.8% – making cement companies jealous. ROE? 83.8%. ROCE? 111%. But don’t faint just yet – those superhero returns are driven by a thin equity base of just ₹23 Cr. P/E is a nose-clogging 57x, Price-to-Book a feverish 44x. Basically, you’re paying luxury real-estate rates for a chemist shelf business.

2. Introduction

The story is simple: Sanofi split its prescription and OTC segments, creating SCHIL as a pure-play consumer healthcare firm. That means no cancer drugs, no vaccines – just the mass-market stuff you pop after a hangover, sinus attack, or when your mom insists you need “Vitamin D drops.”

The product lineup is familiar to every Indian household. Combiflam has been solving headaches since Doordarshan days, Allegra is for when Delhi pollution kicks in, and Avil has been making people drowsy longer than IPL ad breaks. DePURA keeps you from being “Vitamin D deficient” while scrolling Instagram indoors.

The company operates across 29 states, 2 overseas markets, and has a distribution network ranging from big hospital chains to e-commerce. But here’s the twist – despite the OTC familiarity, the stock behaves like it’s selling biotech miracles. 57x P/E for Combiflam and Allegra? That’s like paying for a 5-star buffet and being served Maggi.

3. Business Model – WTF Do They Even Do?

Sanofi Consumer India is basically the FMCG cousin of pharma. Think Dabur but with prescriptions once upon a time. Its business is split into:

• Pain Relief: Combiflam. Market share ~2.5%. Every Indian’s go-to for headaches and “backache after attending shaadi.”
• Allergy Care: Allegra (~8.2% share) and Avil (~6.3% share). The first makes you alert, the second makes you sleepy – so they’ve covered both ends.
• Wellness: DePURA vitamin D drops, essential for those who avoid sunlight like vampires. Market share ~1.5%.

Revenue split: 91% product sales, 6% services (manufacturing tie-ups, contracts), 1% other, 2% interest income.

Distribution: Pharmacies, hospitals, e-commerce, government tenders. Basically, from your neighbourhood Apollo Pharmacy to the dusty government dispensary.

Question: If most Indians buy these brands without even checking labels, how much brand marketing is really needed? Or is nostalgia their real moat?

4. Financials Overview

Commentary: Profit doubled YoY, thanks to strong operating leverage. But QoQ growth looks juiced up by one-off other income (₹12 Cr this quarter). Still, margins above 30% put many FMCGs to shame.

5. Valuation Discussion – Fair Value Range Only

• P/E Method: EPS TTM ~₹86.8. Apply consumer healthcare multiples: 30–40x. Fair Value Range: ₹2,600–₹3,500.
• EV/EBITDA: EV ~₹11,190 Cr, EBITDA TTM ~₹280 Cr. EV/EBITDA ~40x. Peers trade 20–25x. Fair Range: 20–25x EBITDA → EV ₹5,600–₹7,000 Cr → ₹2,500–₹3,100/share.
• DCF (rough cut): Revenue CAGR 8–10%, margin 35%, WACC 11%. Intrinsic range ₹2,800–₹3,600.

🎤 Disclaimer: This fair value range is for educational purposes only and not investment advice.

6. What’s Cooking – News, Triggers, Drama

• Listing (Sep’24): Got demerged and listed, making OTC pharma a standalone story. Traders licked their lips, only to sneeze when P/E touched 70x.
• Open Offer (May’25): Opal Bidco SAS + Clayton, Dubilier & Rice launched open offer for 26% at ₹5.99 Cr total value (tiny compared to market cap). Translation: global PE sniffing around, but scale in India still modest.
• KMP Musical Chairs: CFO Surendra Agarwal resigned in Dec’24, replaced by Maithilee Mistry in Jan’25, who was later replaced by Narahari Naidu in Aug’25 (interim). Clearly, finance heads are rotating faster than a chemist’s billing machine.